56. Behcet disease Clinical trials / Disease details
Clinical trials : 81 / Drugs : 107 - (DrugBank : 30) / Drug target genes : 36 - Drug target pathways : 116
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00483184 (ClinicalTrials.gov) | April 2006 | 5/6/2007 | Low Dose Interferon Alpha Treatment for Oral Ulcers of Behcet's Disease | Phase II Study, Evaluation of Low Dose Natural Human Interferon Alpha Administered by the Oral Mucosal Route in the Treatment of Behçet's Disease | Behcet Syndrome;Behcet Disease;Mucocutaneous Ulceration | Biological: Veldona, | Nobel Pharmaceuticals | Amarillo Biosciences, Inc. | Completed | 18 Years | 75 Years | All | 84 | Phase 2 | Turkey |